Pharma BD Deal Intelligence
Xellia went from a $700M growth bet to a shrinking, impairment-scarred anti-infectives supplier now closing its own Copenhagen plant.
Full analysis, sources & comparables →Novo CEO Henrik Gürtler called the $700M Xellia take-private 'one of the largest investments made by Novo A/S to date,' citing fit with Novo's…
Xellia is a leading global supplier of vancomycin and colistimethate sodium APIs with US operations representing ~60% of revenue by 2018; partnered with Civica…
Civica Rx partnered with Xellia to manufacture generic vancomycin and daptomycin specifically to address chronic US hospital antibiotic shortages — validating…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novo A/S acquired Xellia Pharmaceuticals from 3i and other shareholders for ~$700M; one of Novo Holdings' largest disclosed investments at the time.
Xellia went from a $700M growth bet to a shrinking, impairment-scarred anti-infectives supplier now closing its own Copenhagen plant.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo A/S (Novo Holdings) / Xellia Pharmaceuticals (this deal) | 2013 | $700M | 31 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · Infectious Disease deals